Physician profile
Sarah Jacobs
NPI 1093477713
$1,997.95
in general payments reported to CMS, 2019-2025
22 companies · $511 in 2025
The $511 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $320 · 2023: $561 · 2024: $606 · 2025: $511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,678.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $255.49 | 2022-2023 | Camzyos |
| Abbott Laboratories | $216.81 | 2022-2023 | Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $196.80 | 2024 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $192.35 | 2022-2025 | Lokelma, Farxiga |
| Philips North America LLC | $174.67 | 2024-2025 | (Ck4) Mcot, Extended Holter, Ambulatory Monitoring & Diagnostics Undivided |
| Scpharmaceuticals INC. | $168.82 | 2024-2025 | |
| Boston Scientific Corporation | $135.09 | 2023 | Watchman Access System |
| Lilly USA, LLC | $126.42 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $110.10 | 2023-2025 | Repatha, Repatha, Prolia |
| Novo Nordisk INC | $80.37 | 2025 | Wegovy |
| Heartflow, INC. | $54.97 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $45.82 | 2023-2025 | Verquvo |
| Medtronic, INC. | $42.32 | 2022-2023 | Cobalt Dr Mri Surescan |
| Bayer Healthcare Pharmaceuticals INC. | $40.29 | 2025 | |
| Pfizer INC. | $26.09 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $23.04 | 2023 | Turnpike |
| Edwards Lifesciences Corporation | $22.94 | 2022 | |
| Novartis Pharmaceuticals Corporation | $20.84 | 2024 | |
| Cleerly, INC. | $18.73 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Kiniksa Pharmaceuticals International, Plc | $16.03 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $15.72 | 2025 | Dupixent |
| Esperion Therapeutics, INC. | $14.24 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Jacobs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.